Palbociclib: tested with established drugs
58 studies: they are given beside it. Page 1 of 1. Open to participants first (5), then studies with results posted, then the rest; newest registration first within each.
- Comparing Endocrine Therapy Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Breast CancerNot yet recruitingNCT07061717Phase 3Report a problem
- Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)RecruitingNCT06126276Phase 2Report a problem
- Palbociclib and Pembrolizumab in SarcomaRecruitingNCT06113809Phase 1Report a problem
- A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBCRecruitingNCT05766410Phase 2Report a problem
- Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 InhibitorRecruitingNCT04966481Phase 3Report a problem
- Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)CompletedNCT03792256Phase 1Results postedReport a problem
- To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH)CompletedNCT03644186Phase 2Results postedReport a problem
- T-DM1 and Palbociclib for Metastatic HER2 Breast CancerCompletedNCT03530696Phase 2Results postedReport a problem
- Los Tres Paso: Neoadjuvant Palbociclib Monotherapy, Concurrent Chemoradiation Therapy, Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT03389477Phase 2Results postedReport a problem
- Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast CancerCompletedNCT03007979Phase 2Results postedReport a problem
- Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast CancerActive, not recruitingNCT02947685Phase 3Results postedReport a problem
- Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain MetastasisTerminatedNCT02774681Phase 2Results postedReport a problem
- Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast CancerCompletedNCT02630693Phase 2Results postedReport a problem
- Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast CancerCompletedNCT02536742Phase 2Results postedReport a problem
- PALbociclib CoLlaborative Adjuvant StudyActive, not recruitingNCT02513394Phase 3Results postedReport a problem
- Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast CancerCompletedNCT02499146Phase 1Results postedReport a problem
- Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck CancerCompletedNCT02499120Phase 2Results postedReport a problem
- A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]CompletedNCT02297438Phase 3Results postedReport a problem
- A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast CancerCompletedNCT02296801Phase 2Results postedReport a problem
- PD 0332991 and Cetuximab in Patients With Incurable SCCHNCompletedNCT02101034Phase 1/2Results postedReport a problem
- A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate CancerCompletedNCT02059213Phase 2Results postedReport a problem
- Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast CancerCompletedNCT02040857Phase 2Results postedReport a problem
- Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)CompletedNCT01942135Phase 3Results postedReport a problem
- A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)CompletedNCT01740427Phase 3Results postedReport a problem
- PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast CancerActive, not recruitingNCT01723774Phase 2Results postedReport a problem
- A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast CancerCompletedNCT01684215Phase 2Results postedReport a problem
- Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast CancerCompletedNCT00721409Phase 2Results postedReport a problem
- An Investigational Drug, Palbociclib (PD-0332991), Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma.CompletedNCT00555906Phase 2Results postedReport a problem
- A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)Active, not recruitingNCT05468697Phase 1/2Report a problem
- Palbociclib in Combo w/Chemotherapy in Peds Relapsed/Refractory Acute Lymphoblastic LeukemiaCompletedNCT04996160Phase 1Report a problem
- Tumor Response Time of Palbociclib in Combination With AI in Real-world Chinese PatientsStatus unknownNCT04858997Phase 2Report a problem
- Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast CancerCompletedNCT03969121Phase 3Report a problem
- Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast CancerActive, not recruitingNCT03820830Phase 3Report a problem
- PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA)CompletedNCT03809988Phase 2Report a problem
- The Combination of Palbociclib With ddEC-P as Neoadjuvant Therapy in Triple Negative Breast CancerStatus unknownNCT03756090Not applicableReport a problem
- Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast CancerTerminatedNCT03709082Phase 1/2Report a problem
- Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast CancerActive, not recruitingNCT03573648Phase 2Report a problem
- Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic LeukemiaTerminatedNCT03515200Phase 1Report a problem
- Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to FulvestrantCompletedNCT03447132Phase 3Report a problem
- PAlbociclib Plus Tamoxifen for the Treatment of Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Women - Asian studYActive, not recruitingNCT03423199Phase 3Report a problem
- Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ mBCCompletedNCT03184090Phase 2Report a problem
- PalbocIclib in PreMenopausal Women With ER Positive/HER-2 Negative MetAstatic Breast CancerStatus unknownNCT02917005Phase 2Report a problem
- Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or FulvestrantCompletedNCT02894398Phase 2Report a problem
- Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase InhibitorActive, not recruitingNCT02738866Phase 2Report a problem
- Fulvestrant (F)+Placebo vs F+Palbociclib First Line for Postmenopausal Hormone Receptor+ Advanced Breast CancerStatus unknownNCT02690480Phase 2Report a problem
- Neoadjuvant Response-guided Treatment of Slowly Proliferating Hormone Receptor Positive TumorsActive, not recruitingNCT02592083Phase 2Report a problem
- To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine TherapyCompletedNCT02549430Phase 2Report a problem
- "Neo-Adjuvant Treatment With Palbociclib: Effect on Ki67 and Apoptosis Before, During and After Treatment "CompletedNCT02530424Phase 2Report a problem
- Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1)CompletedNCT01976169Phase 1Report a problem
- A Study To Investigate The Drug-Drug Interaction Potential Of Rifampin OnThe Investigational Agent Palbociclib (PD-0332991)CompletedNCT01953731Phase 1Report a problem
- Drug Interaction Study To Investigate The Potential Effect Of Proton Pump Inhibitor On The Pharmacokinetics Of Palbociclib (PD-0332991)CompletedNCT01918176Phase 1Report a problem
- A Study To Establish The Equivalence Of 2 Palbociclib (PD-0332991) Formulations To The Intended Final Market ProductCompletedNCT01906125Phase 1Report a problem
- A Study To Determine If Coadministration Of Tamoxifen Alters The Extent Or Rate Of Palbociclib (PD-0332991) Absorption Or Elimination In Healthy Male VolunteersCompletedNCT01821066Phase 1Report a problem
- A Drug-Drug Interaction Study To Investigate The Potential For Multiple Doses Of Palbociclib (PD-0332991) To Alter The Pharmacokinetics Of Oral Midazolam In Adult Healthy Women of Non-Childbearing Potential.CompletedNCT01756781Phase 1Report a problem
- Letrozole and CDK 4/6 Inhibitor for ER Positive, HER2 Negative Breast Cancer in Postmenopausal WomenStatus unknownNCT01709370Phase 2Report a problem
- PD-0332991, 5-FU, and Oxaliplatin for Advanced Solid Tumor MalignanciesStatus unknownNCT01522989Phase 1Report a problem
- PD0332991/Paclitaxel in Advanced Breast CancerCompletedNCT01320592Phase 1Report a problem
- Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell LymphomaTerminatedNCT01111188Phase 1Report a problem